Proteomics discovery of novel biomarkers for diagnosis and stratification of patient at risk for atherosclerotic cardiovascular diseases
Atherosclerotic coronary artery disease (CAD)-related deaths will continue to rise along with global population ageing. Although established conventional risk factors are in place for the prediction of cardiovascular (CV) events, however, the absence does not necessarily imply zero CAD risk. Effe...
Saved in:
Main Author: | |
---|---|
Other Authors: | |
Format: | Theses and Dissertations |
Language: | English |
Published: |
2017
|
Subjects: | |
Online Access: | http://hdl.handle.net/10356/70615 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Summary: | Atherosclerotic coronary artery disease (CAD)-related deaths will continue to rise
along with global population ageing. Although established conventional risk factors
are in place for the prediction of cardiovascular (CV) events, however, the absence
does not necessarily imply zero CAD risk. Effective screening and diagnostic
methods that stratify patient at high risk for CAD, before onset of acute events,
remain unsatisfactory, necessitating the search for novel measurable protein
biomarkers. Thankfully, biomarker discovery has taken a leap forward with the
development of mass spectrometry (MS)-based proteomics approaches, which
afforded the interrogation of the plasma proteome. The incomplete understanding in
the mechanisms in plaque destabilization and rupture, creates a knowledge gap in
the pathophysiological underlying atherosclerosis and myocardial infraction (MI). In
addition, currently there is no plasma-based screening assay that effectively
differentiates atherosclerosis from MI. The development of innovative techniques
that improves the detectable range of plasma pro teo me, is essential in advancing the
field of plasma-based biomarker discovery research. My PhD research work has
been divided into four parts (I - IV), the first three parts showcased the clinical utility
of the plasma proteome for CAD proteomics-based biomarker discovery, and in the
final part, and the successful development of a novel enrichment strategy for plasma
glycoproteins and extracellular vesicles (EV) was demonstrated. Herein, the careful
selection and systematic integration of several proteomics strategies have proven
useful in the discovery of novel plasma biomarkers of CAD, derived from (i)
undepleted plasma proteome, (ii) EV plasma proteome and (iii) carbamylated plasma
proteome. Functional linkage analyses have prompted the generation of new
hypotheses into the pathophysiological states that specifies either for atherosclerosis
or myocardial injury. The novel plasma sub-proteome enrichment technique
described here have afforded the detection of low-abundant proteins with
concentration ranging from pg/mL- ng/mL in crude plasma. In essence, this thesis
demonstrates the applicability and reliability of the different proteomics platforms in
the discovery and development of useful biomarkers that are predictive of CAD. |
---|